Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic Breast Cancer Age: Adult Condition: HER2-positive metastatic breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease |
Dose: Intravenous infusion – 840 mg initial dose, then 420 mg Frequency: Every 3 weeks Note: Initial dose over 60 minutes, then subsequent doses over 30-60 minutes. Administered in combination with trastuzumab and docetaxel. |
|
Indication: Neoadjuvant Treatment of Breast Cancer Age: Adult Condition: HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen |
Dose: Intravenous infusion – 840 mg initial dose, then 420 mg Frequency: Every 3 weeks Note: Initial dose over 60 minutes, then subsequent doses over 30-60 minutes. Administered in combination with trastuzumab and docetaxel. Following surgery, patients should continue to receive trastuzumab to complete 1 year of treatment. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Tablet – No approved pediatric dosage available Note: No approved pediatric dosage available |
Administration
- Given as IV infusion
- Initial dose over 60 minutes
Side Effect
- Diarrhea (66.8%)
- Alopecia (60.9%)
- Neutropenia (52.8%)
- Nausea (42.3%)
- Fatigue (37.6%)
- Rash (33.7%)
- Peripheral neuropathy (32.4%)
- Decreased appetite (29.2%)
- Mucosal inflammation (27.8%)
- Asthenia (26%)
- Vomiting (24.1%)
- Anemia (23.1%)
- Peripheral edema (23.1%)
- Nail disorder (22.9%)
- Myalgia (22.9%)
- Headache (20.9%)
- Stomatitis (18.9%)
- Pyrexia (18.7%)
- Dysgeusia (18.4%)
- Leukopenia (18.2%)
- Upper respiratory tract infection (URTI) (16.7%)
- Arthralgia (15.5%)
- Constipation (15%)
- Pruritus (14%)
- Dyspnea (14%)
- Increased lacrimation (14%)
- Febrile neutropenia (13.8%)
- Insomnia (13.3%)
- Dizziness (12.5%)
- Nasopharyngitis (11.8%)
- Dry skin (10.6%)
- Hypersensitivity (10%)
- Paronychia (7.1%)
- Pleural effusion (5.2%)
- Left ventricular dysfunction (4.4%)
- Congestive heart failure (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
No interactions listed
|
-
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store vials in a refrigerator at 2°C to 8°C until time of use. Keep vial in the outer carton in order to protect from light.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.